A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ENACT
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 18 May 2017 Planned End Date changed from 1 Apr 2019 to 31 Mar 2020.